• to decrease the potential risk of significant cardiovascular (heart and blood vessel) challenges in adults with form two diabetes and cardiovascular diseaseThis led Novo Nordisk to perform even further investigate into better dosages of semaglutide especially for weight management.He has also attributed the higher price ranges within the U.S. t